Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY
There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More 
Unstructured EHR data more useful for predictive analytics, study shows
A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More 
Cannabis for Treating IBD: Hope or Hype?
Nausea, abdominal pain and changes in appetite. These are all things that can significantly impact one’s wellbeing if left untreated, yet they have all shown marked improvements when associated with cannabis. Yet, less is known about the effects of cannabis on inflammatory bowel disease, or IBD, a chronic inflammatory condition that impacts the gastrointestinal tract…
Read More 
The Lack of Clinical Trials in the Medical Marijuana Industry
As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical…
Read More 
New Feature: Text Message Treatment Updates
New to the Arfinn Med portal comes the ability to receive real time updates from patients via text messaging. This new addition will allow physicians to stay up to date on current patient efficacies as well as streamline the data collection process. Through the new text messaging function, physicians are able to send patients automated…
Read More 
COVID-19 and medical cannabis patients: What you need to know
In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More